RS
LFCR icon

R Squared’s Lifecore Biomedical LFCR Stock Holding History

R Squared’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Buy
+24,580
New +$124K 0.07% 385

Other funds holding LFCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CA
CWC Advisors Lake Oswego, Oregon $225M AUM 23.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DT
DBA Trading Fort Lauderdale, Florida $199M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MAA
Mraz Amerine & Associates Modesto, California $697M AUM 19.37% 1-Year Est. Return

R Squared's LFCR Position: Q2 2026 in Review

R Squared opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 24,580 shares worth $129K. The stake represents 0.07% of the portfolio and ranks #385 among its holdings.

33 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • R Squared held 24,580 shares of Lifecore Biomedical worth $129K as of Q2 2026.
  • Lifecore Biomedical was a new R Squared position in Q2 2026.
  • Lifecore Biomedical made up 0.07% of R Squared's portfolio in Q2 2026, its #385 holding.
  • 33 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.